Komori
Nippon Shinyaku (4516) · InitiativeFirst stated

Introduction of C21, a treatment for idiopathic pulmonary fibrosis

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
C21 licensing agreement (treatment for idiopathic pulmonary fibrosis)A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「License agreement for the exclusive development and commercialisation rights to C21, a treatment for idiopathic pulmonary fibrosis」

    The company entered into an agreement with Vicore Pharma in February 2024 to license the exclusive development and commercialisation rights to C21.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nippon Shinyaku's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.